Abstract
The gastrointestinal tract (GIT) is a long and complex organ, with significantly variable characteristics throughout. It is broadly divided to several segments: the stomach; the small intestine which is subdivided to duodenum, jejunum, and ileum; and the colon. Each segment has its own unique environment. Conditions in each segment are dependent on a multitude of factors. The focus of this chapter is gastroretentive dosage form (GRDF). This term encompasses several technologies with one common feature: they are designed to resist the normal tendency of the stomach to clear its content, resulting in a targeted and controlled release of the active moiety to the upper GI tract. A special emphasis is given for the rationale for GRDF, different GRDF technologies, and their unique application. In conclusion, segment-specific targeting technologies are a highly important research field; a thorough understanding of the determinants of gastrointestinal environment, considering the whole of the human intestine, is crucial for successful targeting of drugs to specific gastrointestinal regions and exploitation of the variable intestinal conditions for better drug delivery and therapeutic effect.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Dahan A, Amidon GL (2009) Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm 6(1):19–28
Dahan A, Lennernäs H, Amidon GL (2012) The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm 9(6):1847–1851
Dahan A, West BT, Amidon GL (2009) Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci 36(2–3):320–329
Dahan A, Amidon GL, Zimmermann EM (2010) Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update. Expert Rev Clin Immunol 6(4):543–550
Streubel A, Siepmann J, Bodmeier R (2006) Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol 6(5):501–508
Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16(5):351–380
Washington N, Washington C, Wilson CG (eds) (2003) Physiological pharmaceutics barriers to drug absorption. Taylor & Francis e-Library, London
Lahner E, Annibale B, Delle Fave G (2009) Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 29(4):379–386
Ogawa R, Echizen H (2011) Clinically significant drug interactions with antacids: an update. Drugs 71(14):1839–1864
Berthet S, Charpiat B, Mabrut JY (2010) Erythromycin as a prokinetic agent: risk factors. J Visc Surg 147(2):e13–e18
Kagan L, Hoffman A (2008) Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Expert Opin Drug Deliv 5(6):681–692
Englund G et al (2006) Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29(3–4):269–277
Chan LM, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21(1):25–51
Dahan A, Sabit H, Amidon GL (2009) Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 37(10):2028–2036
Bardonnet PL et al (2006) Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release 111(1–2):1–18
Kagan L, Hoffman A (2008) Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model. Eur J Pharm Biopharm 69(1):238–246
Chauhan B et al (2005) Preparation and evaluation of floating risedronate sodium-Gelucire 43/01 formulations. Drug Dev Ind Pharm 31(9):851–860
Li S et al (2001) Statistical optimization of gastric floating system for oral controlled delivery of calcium. AAPS PharmSciTech 2(1):E1
Nur AO, Zhang JS (2000) Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Dev Ind Pharm 26(9):965–969
Chavanpatil M et al (2005) Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Int J Pharm 304(1–2):178–184
Wei Z, Yu Z, Bi D (2001) Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug. Drug Dev Ind Pharm 27(5):469–474
Hu L et al (2011) Floating matrix dosage form for dextromethorphan hydrobromide based on gas forming technique: in vitro and in vivo evaluation in healthy volunteers. Eur J Pharm Sci 42(1–2):99–105
Gambhire MN et al (2007) Development and in vitro evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride. AAPS PharmSciTech 8(3):E73
Patel VF, Patel NM (2007) Statistical evaluation of influence of viscosity and content of polymer on dipyridamole release from floating matrix tablets: a technical note. AAPS PharmSciTech 8(3):E69
Chowdary KP, Rao YS (2003) Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: a technical note. AAPS PharmSciTech 4(3):E39
El-Kamel AH et al (2001) Preparation and evaluation of ketoprofen floating oral delivery system. Int J Pharm 220(1–2):13–21
Stepensky D et al (2001) Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J Control Release 71(1):107–115
Strubing S, Metz H, Mader K (2008) Characterization of poly(vinyl acetate) based floating matrix tablets. J Control Release 126(2):149–155
Dave BS, Amin AF, Patel MM (2004) Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS PharmSciTech 5(2):e34
Hejazi R, Amiji M (2003) Stomach-specific anti-H. pylori therapy. II. Gastric residence studies of tetracycline-loaded chitosan microspheres in gerbils. Pharm Dev Technol 8(3):253–262
Sawicki W (2002) Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. Eur J Pharm Biopharm 53(1):29–35
Bagul US et al (2011) Stomach specific drug delivery systems: a review. Int J Pharm Res Dev 4(4):147–150
Deshpande AA et al (1997) Development of a novel controlled-release system for gastric retention. Pharm Res 14(6):815–819
Makwana A et al (2012) Advancements in controlled release gastroretentive drug delivery systems: a review. J Drug Deliv Ther 2(3):12–21
Jaimini M, Rana AC, Tanwar YS (2007) Formulation and evaluation of famotidine floating tablets. Curr Drug Deliv 4(1):51–55
Mazer N et al (1988) Intragastric behavior and absorption kinetics of a normal and “floating” modified-release capsule of isradipine under fasted and fed conditions. J Pharm Sci 77(8):647–657
Saito N et al (2003) Plural transformation-processes from spiral to coccoid Helicobacter pylori and its viability. J Infect 46(1):49–55
Singh BN, Kim KH (2000) Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 63(3):235–259
Reddy LH, Murthy RS (2002) Floating dosage systems in drug delivery. Crit Rev Ther Drug Carrier Syst 19(6):553–585
Hwang SJ, Park H, Park K (1998) Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 15(3):243–284
Ali J et al (2007) Formulation and development of hydrodynamically balanced system for metformin: in vitro and in vivo evaluation. Eur J Pharm Biopharm 67(1):196–201
Hamdani J et al (2006) In vitro and in vivo evaluation of floating riboflavin pellets developed using the melt pelletization process. Int J Pharm 323(1–2):86–92
Ritschel WA (1991) Targeting in the gastrointestinal tract: new approaches. Methods Find Exp Clin Pharmacol 13(5):313–336
Erdeve O et al (2011) Efficacy and safety of sodium alginate for GERD in preterm infants. Aliment Pharmacol Ther 33(8):981–982, author reply 982–3
Kwiatek MA et al (2011) An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther 34(1):59–66
Strugala V et al (2009) The role of an alginate suspension on pepsin and bile acids - key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease? J Pharm Pharmacol 61(8):1021–1028
Sato Y et al (2004) Pharmacoscintigraphic evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans. J Control Release 98(1):75–85
Streubel A, Siepmann J, Bodmeier R (2002) Floating microparticles based on low density foam powder. Int J Pharm 241(2):279–292
Streubel A, Siepmann J, Bodmeier R (2003) Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci 18(1):37–45
Streubel A, Siepmann J, Bodmeier R (2003) Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles. J Microencapsul 20(3):329–347
Talukder R, Fassihi R (2004) Gastroretentive delivery systems: hollow beads. Drug Dev Ind Pharm 30(4):405–412
Kedzierewicz F et al (1999) Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J Control Release 58(2):195–205
Klausner EA et al (2003) Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J Control Release 88(1):117–126
Chen J et al (2000) Gastric retention properties of superporous hydrogel composites. J Control Release 64(1–3):39–51
Huang Y et al (2000) Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J Control Release 65(1–2):63–71
Vasir JK, Tambwekar K, Garg S (2003) Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 255(1–2):13–32
Singh B et al (2012) Formulation development of gastroretentive tablets of lamivudine using the floating-bioadhesive potential of optimized polymer blends. J Pharm Pharmacol 64(5):654–669
Groning R, Berntgen M, Georgarakis M (1998) Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Eur J Pharm Biopharm 46(3):285–291
Bhandari A, Crowe SE (2012) Helicobacter pylori in gastric malignancies. Curr Gastroenterol Rep 14(6):489–496
Suerbaum S, Michetti P (2002) Helicobacter pylori infection. N Engl J Med 347(15):1175–1186
Conway BR (2005) Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr Pharm Des 11(6):775–790
Noonan B, Alm RA (2002) Novel intervention strategies for Helicobacter pylori treatment. Curr Drug Targets Infect Disord 2(4):331–338
Touati E (2010) When bacteria become mutagenic and carcinogenic: lessons from H. pylori. Mutat Res 703(1):66–70
Malfertheiner P et al (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56(6):772–781
Niv Y (2008) H pylori recurrence after successful eradication. World J Gastroenterol 14(10):1477–1478
Megraud F (2004) H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53(9):1374–1384
De Francesco V et al (2010) Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 19(4):409–414
Yang L, Eshraghi J, Fassihi R (1999) A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. J Control Release 57(3):215–222
Liu Z et al (2005) In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J Control Release 102(1):135–144
Umamaheshwari RB, Jain NK (2004) Receptor-mediated targeting of lipobeads bearing acetohydroxamic acid for eradication of Helicobacter pylori. J Control Release 99(1):27–40
Iijima K et al (2004) Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. Aliment Pharmacol Ther 19(11):1181–1188
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Controlled Release Society
About this chapter
Cite this chapter
Wolk, O., Dahan, A. (2014). Segmental-Dependent Drug Absorption and Delivery: The Stomach. In: Domb, A., Khan, W. (eds) Focal Controlled Drug Delivery. Advances in Delivery Science and Technology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-9434-8_15
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9434-8_15
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-9433-1
Online ISBN: 978-1-4614-9434-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)